TGTX

TG Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · tgtherapeutics.com

$35.70

Mkt Cap $5.7B

52w Low $25.28 66.4% of range 52w High $40.99

50d MA $32.11 200d MA $31.87

P/E (TTM) 10.9x

EV/EBITDA 33.4x

P/B 7.5x

Debt/Equity 0.4x

ROE 69.0%

P/FCF -172.2x

RSI (14) —

ATR (14) —

Beta 1.75

50d MA $32.11

200d MA $31.87

Avg Volume 1.9M

About

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), an…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	0.35	0.14	-60.0%	30.90	-1.1%	-2.6%	-4.9%	-6.5%	-5.5%	-6.1%	—
Nov 3, 2025	AMC	0.24	2.43	+912.5%	33.69	-1.8%	+0.4%	+1.0%	-1.3%	-4.3%	-10.1%	—
Aug 4, 2025	AMC	0.32	0.17	-46.9%	28.72	+1.3%	-1.1%	-3.6%	-2.9%	-7.0%	-8.1%	—
May 5, 2025	AMC	0.18	0.03	-83.3%	37.68	-1.1%	-7.5%	-7.5%	-10.1%	-10.7%	-7.1%	—
Mar 3, 2025	AMC	0.08	0.15	+87.5%	34.42	+0.0%	+3.5%	+2.0%	+2.2%	+11.7%	+14.0%	—
Nov 4, 2024	AMC	0.03	0.02	-33.3%	24.36	+0.5%	+6.2%	+11.5%	+14.5%	+18.3%	+26.2%	—
Aug 6, 2024	AMC	-0.05	0.04	+180.0%	20.58	+4.0%	-2.9%	-2.6%	-3.2%	+0.3%	+3.2%	—
May 1, 2024	AMC	-0.04	-0.07	-96.1%	15.88	+2.0%	+3.4%	+2.0%	+4.0%	+8.2%	+7.8%	—
Feb 28, 2024	AMC	-0.12	-0.09	+25.0%	17.63	+1.2%	-2.3%	+1.9%	+1.4%	+2.6%	+3.4%	—
Nov 1, 2023	AMC	0.12	0.73	+508.3%	10.12	+0.0%	+2.9%	+9.3%	+1.3%	+7.0%	+6.6%	—
Aug 1, 2023	AMC	-0.26	-0.34	-30.8%	10.49	+1.7%	+0.6%	+6.8%	+2.1%	-3.7%	-8.0%	—
May 1, 2023	AMC	-0.36	-0.28	+22.2%	30.64	+0.6%	+1.7%	+13.8%	+14.2%	+11.9%	+8.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 2	JP Morgan	Maintains	Overweight → Overweight	—	$29.43	$29.20	-0.8%	-0.8%	+1.0%	-1.1%	-5.7%	-1.9%
Jan 15	Goldman Sachs	Maintains	Neutral → Neutral	—	$29.54	$29.54	+0.0%	+4.0%	+3.5%	+4.7%	+6.9%	+7.1%
Nov 3	JP Morgan	Maintains	Overweight → Overweight	—	$34.78	$36.30	+4.4%	-3.1%	-2.8%	-2.1%	-4.4%	-7.3%
Sep 17	B. Riley Securities	Maintains	Buy → Buy	—	$31.99	$32.16	+0.5%	+0.2%	+1.9%	+1.2%	+9.3%	+11.2%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.42	$34.42	+0.0%	+3.5%	+2.0%	+2.2%	+11.7%	+14.0%
Jan 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.74	$30.67	+3.1%	+1.5%	-2.0%	-0.6%	+0.4%	-2.0%
Nov 25	JP Morgan	Maintains	Overweight → Overweight	—	$35.07	$35.89	+2.3%	-1.3%	-2.3%	-0.2%	-0.8%	+0.1%
Nov 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.36	$24.49	+0.5%	+6.2%	+11.5%	+14.5%	+18.3%	+26.2%
Nov 5	Goldman Sachs	Maintains	Neutral → Neutral	—	$24.36	$24.49	+0.5%	+6.2%	+11.5%	+14.5%	+18.3%	+26.2%
Sep 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.08	$26.25	+4.7%	+0.7%	+0.8%	-1.7%	-7.3%	-7.1%
Aug 7	Goldman Sachs	Maintains	Neutral → Neutral	—	$20.58	$21.40	+4.0%	-2.9%	-2.6%	-3.2%	+0.3%	+3.2%
Aug 7	B. Riley Securities	Maintains	Buy → Buy	—	$20.58	$21.40	+4.0%	-2.9%	-2.6%	-3.2%	+0.3%	+3.2%
Aug 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.21	$19.07	+10.8%	+19.6%	+16.2%	+16.4%	+15.7%	+20.0%
May 2	Ladenburg Thalmann	Maintains	Buy → Buy	—	$15.88	$16.20	+2.0%	+3.4%	+2.0%	+4.0%	+8.2%	+7.8%
May 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.88	$16.20	+2.0%	+3.4%	+2.0%	+4.0%	+8.2%	+7.8%
Apr 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.82	$13.99	+1.2%	+1.2%	-0.3%	+2.0%	+3.1%	+1.2%
Apr 18	JP Morgan	Maintains	Overweight → Overweight	—	$13.82	$13.99	+1.2%	+1.2%	-0.3%	+2.0%	+3.1%	+1.2%
Apr 18	Ladenburg Thalmann	Maintains	Buy → Buy	—	$13.82	$13.99	+1.2%	+1.2%	-0.3%	+2.0%	+3.1%	+1.2%
Mar 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.22	$17.54	+1.9%	+4.3%	+3.8%	+5.0%	+5.9%	+4.5%
Feb 29	Goldman Sachs	Maintains	Neutral → Neutral	—	$17.63	$17.85	+1.2%	-2.3%	+1.9%	+1.4%	+2.6%	+3.4%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.91	$16.18	+16.3%	+26.7%	+23.8%	+29.1%	+28.5%	+30.0%
Feb 5	B. Riley Securities	Maintains	Buy → Buy	—	$16.46	$16.48	+0.1%	-7.0%	-6.7%	-12.7%	-11.1%	-10.4%
Jan 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.77	$17.68	-0.5%	-3.1%	-11.3%	-14.7%	-13.9%	-14.8%
Nov 1	JP Morgan	Maintains	Overweight → Overweight	—	$7.73	$10.19	+31.8%	+30.9%	+34.7%	+43.1%	+32.6%	+40.1%
Nov 1	Jefferies	Maintains	Buy → Buy	—	$7.73	$10.19	+31.8%	+30.9%	+34.7%	+43.1%	+32.6%	+40.1%
Oct 20	B. Riley Securities	Maintains	Buy → Buy	—	$6.68	$6.68	+0.0%	+1.0%	+0.1%	+10.9%	+5.1%	+7.8%
Sep 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.14	$10.00	-1.4%	-6.2%	-5.4%	-8.3%	-8.8%	-9.9%
Aug 7	JP Morgan	Maintains	Overweight → Overweight	—	$10.71	$10.65	-0.6%	-5.7%	-9.9%	-9.6%	-9.4%	-5.4%
Aug 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$10.55	$10.59	+0.4%	+6.2%	+1.5%	-4.3%	-8.5%	-8.2%
Aug 2	Goldman Sachs	Upgrade	Sell → Neutral	—	$10.49	$10.67	+1.7%	+0.6%	+6.8%	+2.1%	-3.7%	-8.0%
Aug 2	B. Riley Securities	Maintains	Buy → Buy	—	$10.49	$10.67	+1.7%	+0.6%	+6.8%	+2.1%	-3.7%	-8.0%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.69	$11.88	-42.6%	-49.3%	-49.0%	-45.9%	-48.2%	-51.2%
Aug 1	B. Riley Securities	Maintains	Buy → Buy	—	$20.69	$11.88	-42.6%	-49.3%	-49.0%	-45.9%	-48.2%	-51.2%
Jul 25	Goldman Sachs	Maintains	Sell → Sell	—	$20.28	$20.24	-0.2%	-0.7%	-0.2%	-2.3%	-2.9%	+2.0%
Jul 24	Goldman Sachs	Maintains	Sell → Sell	—	$20.62	$20.65	+0.1%	-1.6%	-2.3%	-1.9%	-3.9%	-4.5%
Jul 13	B. Riley Securities	Maintains	Buy → Buy	—	$25.46	$23.00	-9.7%	-14.6%	-13.2%	-15.6%	-16.1%	-16.6%
May 2	Ladenburg Thalmann	Maintains	Buy → Buy	—	$30.64	$30.82	+0.6%	+1.7%	+13.8%	+14.2%	+11.9%	+8.0%
Feb 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$18.48	$18.73	+1.4%	-0.3%	-3.1%	-5.2%	-3.1%	-0.5%
Jan 24	Evercore ISI	Maintains	Outperform → Outperform	—	$12.69	$13.18	+3.9%	+14.0%	+12.1%	+11.5%	+15.3%	+14.3%
Dec 30	Goldman Sachs	Maintains	Sell → Sell	—	$10.40	$10.91	+4.9%	+13.8%	+11.2%	+3.1%	-1.6%	+3.8%
Dec 30	Evercore ISI	Maintains	Outperform → Outperform	—	$10.40	$10.91	+4.9%	+13.8%	+11.2%	+3.1%	-1.6%	+3.8%
Dec 30	B. Riley Securities	Maintains	Buy → Buy	—	$10.40	$10.91	+4.9%	+13.8%	+11.2%	+3.1%	-1.6%	+3.8%
Dec 29	BofA Securities	Maintains	Underperform → Underperform	—	$8.46	$9.18	+8.5%	+22.9%	+39.8%	+36.8%	+26.7%	+20.9%
Dec 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.46	$9.18	+8.5%	+22.9%	+39.8%	+36.8%	+26.7%	+20.9%
Jun 13	B. Riley Securities	Maintains	Buy → Buy	—	$4.59	$4.40	-4.1%	-10.0%	-16.1%	-15.7%	-18.5%	-12.0%
Apr 19	B. Riley Securities	Maintains	Buy → Buy	—	$6.92	$6.76	-2.3%	+4.9%	+11.1%	+7.2%	+3.0%	+7.9%
Apr 19	Goldman Sachs	Maintains	Sell → Sell	—	$6.92	$6.76	-2.3%	+4.9%	+11.1%	+7.2%	+3.0%	+7.9%
Apr 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.85	$6.03	-31.9%	-21.8%	-18.0%	-13.1%	-16.2%	-19.4%
Jan 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.27	$8.46	+2.3%	+17.7%	+39.9%	+42.3%	+32.8%	+22.6%
Jan 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.57	$13.50	-0.5%	+6.6%	+8.8%	+2.4%	-39.1%	-28.3%

Recent Filings

8-K · 1.01 !! High

Unknown — 8-K 1.01: Material Agreement

Without specific details about the material agreement's terms, financial impact, or strategic importance, investors cannot assess whether this development positively or negatively affects shareholder value.

Mar 20

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

The departure of TGTX's Chief Strategy Officer and Head of Commercial signals potential disruption to commercial execution and strategic planning during a critical period for the biotech company.

Mar 17

8-K

TG Therapeutics, Inc. -- 8-K Filing

TG Therapeutics raised 2026 revenue guidance to $875-900 million on strong 2025 BRIUMVI sales of $594.1 million, signaling robust commercial momentum for its key drug.

Feb 26

Data updated apr 27, 2026 4:39am · Source: massive.com